000250.KQ earnings date and last-quarter result: P/E 378.19. Updated 2026-07-23.
Sam Chun Dang Pharm (000250.KQ) Research Hub
Sam Chun Dang Pharm (000250.KQ) trades on KOE, KR in the Healthcare (Medical - Pharmaceuticals) sector. As of 2026-11-05, shares last closed at 176,600 KRW (+0.46%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 378.19, market cap 3576.66B. This hub links to the full technical, earnings and options research available for 000250.KQ.
Last updated 2026-11-05 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Pharmaceuticals) |
|---|---|
| Exchange | KOE, KR |
| Last close | 176,600 KRW (+0.46%) |
| 52-week range | 120,000 KRW – 294,000 KRW |
| Trend regime | Range |
| 14-day RSI | 30.8 (Bearish) |
| Trailing P/E | 378.19 |
| Market cap | 3576.66B |
| Dividend yield | 0.03% |
Available research for 000250.KQ
Covered Call on 000250.KQ: how it works, illustrative setup around the real 176,600 KRW price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on 000250.KQ: how it works, illustrative setup around the real 176,600 KRW price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on 000250.KQ: how it works, illustrative setup around the real 176,600 KRW price, max profit/loss, breakeven and when to use it. Educational.
000250.KQ technical analysis: range, last 176,600 KRW, RSI 30.8, 52w range 120,000 KRW–294,000 KRW, real support/resistance. Updated 2026-11-05.
More on SniperIQ
Frequently asked questions
What sector is 000250.KQ in?
Sam Chun Dang Pharm (000250.KQ) is classified under Healthcare (Medical - Pharmaceuticals), listed on KOE, KR.
Is 000250.KQ in an uptrend or downtrend?
As of 2026-11-05, 000250.KQ is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is 000250.KQ's trailing P/E ratio?
000250.KQ's trailing P/E is 378.19, with a market cap of 3576.66B. See the earnings research page for full valuation detail.